Hemangioma Clinical Trial
Official title:
Role of Propranolol as Compared to Bleomycin in Management of Hemangioma
NCT number | NCT05327309 |
Other study ID # | 166SZABMU |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 8, 2015 |
Est. completion date | January 1, 2018 |
Verified date | September 2023 |
Source | Shaheed Zulfiqar Ali Bhutto Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Infantile hemangiomas are widespread vascular tumours having incidence of 10% and most of them involute spontaneously. However, they are known to be located in proximity of vital organs and can have poor cosmetic and functional sequel if left untreated. A wide range of treatment options are available from expectant therapy to radical surgical excision. Propanolol has also been shown to be effective in treating infantile cutaneous hemangiomas. Similarly, anti-metabolite drugs as bleomycin has also shown promising results. Efficacy in terms of reduction in size of both treatments has been scarcely studied especially in Pakistan. OBJECTIVE: To assess the efficacy of oral propranolol and intraleisonal bleomycin in the treatment of infantile cutaneous hemangioma in terms of size regression
Status | Completed |
Enrollment | 90 |
Est. completion date | January 1, 2018 |
Est. primary completion date | May 9, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months to 12 Months |
Eligibility | Inclusion Criteria: - 1. 6 month to 12 yr. of age presenting with infantile hemangioma anywhere on body 2. Both sex included 3. Previously not treated Exclusion Criteria: On the basis of history and clinical assessment; 1. Patients with previous treatment of hemangioma. 2. Patients who will be lost to follow up 3. Patients who refused to be enrolled in this study 4. Patients who experienced hypersensitivity to propranolol/Bleomycin during treatment or had previous known allergy to the drugs. 5. Patients who had diagnosed Cardiac disease such as heart failure or AV block. 6. Patients with diagnosed Pulmonary disease such as asthma or bronchiolitis. 7. History of impaired renal or liver functions. 8. Diabetes mellitus - |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Shaheed Zulfiqar Ali Bhutto Medical University |
Thayal PK, Bhandari PS, Sarin YK. Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas. Plast Reconstr Surg. 2012 Apr;129(4):733e-735e. doi: 10.1097/PRS.0b013e318245e739. No abstract available. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Size change | Size change:
It is defined as change in size at three or six months compared to baseline size of hemangioma and represented in terms of percentage. Percentage size change = Size of hemangioma at 3 or 6 months x 100 Initial Size Left over Signs after treatment: defined as development of scar, hyperpigmentation or change in texture of skin at the location where hemangioma was previously present. Efficacy: The efficacy of propranolol and bleomycin will be evaluated for change in the size of the lesion, change in the colour of the lesion, epithelialisation in case of ulceration, complications following therapy, and signs of relapse after therapy. The outcome based on change in size will be graded as follows: I Complete involution, implying greater than 90percent response. II Response of change in size of 75 to 90percent III Response of change in size of 50 to 75percent. IV Response of change in size of 25 to 50 percent |
02 years | |
Primary | Size Regression Efficacy Complications: | Objective To evaluate the efficacy of oral propranolol as compared to intralesional Bleomycin in management of cutaneous infantile hemangioma in terms of size change.
Operational Definition Infantile Hemangiomas: These are vascular neoplasms which are lesions characterized by abnormal proliferation of endothelial cells and aberrant blood vessel architecture which proliferate after birth and are diagnosed clinically as cherry red vascular lesions. Complications: Propranolol: The known complications which could be present in group taking propranolol were hypotension, pulmonary symptoms as wheeze and precipitation of asthma and hypoglycemia. These findings were carefully looked for in the group taking propranolol. Bleomycin: The known complications which could be present in group taking bleomycin were Pulmonary symptoms as shortness of breath, bleeding and ulceration of lesions. These symptoms and signs were monitored in patients who were give intra-lesional bleomycin. |
2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01685398 -
Topical Timolol for Superficial Infantile Hemangioma
|
Phase 3 | |
Withdrawn |
NCT00974129 -
A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas
|
N/A | |
Completed |
NCT00374335 -
Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
|
N/A | |
Recruiting |
NCT03331744 -
Clinical Characteristics of Infantile Hemangioma
|
||
Completed |
NCT02342275 -
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
|
Phase 3 | |
Completed |
NCT00433940 -
Immune Suppression Of Infants Treated With Steroids
|
N/A | |
Completed |
NCT04065217 -
The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial
|
N/A | |
Terminated |
NCT01743885 -
Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma
|
Phase 3 | |
Terminated |
NCT00555464 -
Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas
|
Phase 2 | |
Completed |
NCT00394888 -
Hemangioma Associated With High Rates of Morbidity
|
N/A | |
Completed |
NCT02145884 -
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
|
Phase 2 | |
Completed |
NCT04077515 -
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
|
Phase 4 | |
Completed |
NCT02731287 -
Topical Timolol for Infantile Hemangioma in Early Proliferative Phase
|
Phase 2 | |
Recruiting |
NCT01147601 -
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
|
Phase 0 | |
Completed |
NCT01908972 -
The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
|
Phase 4 | |
Completed |
NCT00540566 -
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
|
||
Completed |
NCT00001417 -
Direct Injection of Alcohol for the Treatment of Spinal Tumors
|
N/A | |
Completed |
NCT00004436 -
Randomized Study of Hormonal Regulation of Infantile Hemangioma
|
N/A | |
Recruiting |
NCT02496013 -
Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB
|
Phase 1 | |
Completed |
NCT01072045 -
Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma
|
Phase 2 |